Protalix BioTherapeutics (PLX) Gross Margin (2010 - 2026)

Protalix BioTherapeutics' Gross Margin history runs 17 years deep, the most recent figure standing at 87.77% for Q1 2026.

• On a quarterly basis, Gross Margin rose 6866.0% year-over-year to 87.77% in Q1 2026; TTM through Mar 2026 was 69.97%, a 1999.0% increase from a year earlier, with the FY2025 full-year figure at 48.82%, down 564.0% from the prior year.
• Gross Margin advanced to 87.77% in Q1 2026 per PLX's latest filing, from 49.36% in the prior quarter.
• Across five years, Gross Margin topped out at 87.77% in Q1 2026 and bottomed at 15.54% in Q4 2023.
• The 5-year median for Gross Margin is 53.37% (2024), against an average of 54.19%.
• Across the five-year window, Gross Margin sank 5664 bps in 2023 and soared 6866 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 72.18% in 2022, then sank by 78 bps to 15.54% in 2023, then surged by 406 bps to 78.67% in 2024, then tumbled by 37 bps to 49.36% in 2025, then surged by 78 bps to 87.77% in 2026.
• Per Business Quant, the three latest PLX Gross Margin figures stand at 87.77% (Q1 2026), 49.36% (Q4 2025), and 53.37% (Q3 2025).